RNAZ
Income statement / Annual
Last year (2023), TransCode Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, TransCode Therapeutics, Inc.'s net income was -$18.55 M.
See TransCode Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$516,746.00 |
$98,606.00 |
$42,470.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$516,746.00 |
-$98,606.00 |
-$42,470.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$12.26 M
|
$10.23 M
|
$2.75 M
|
$284,459.00
|
$226,309.00
|
$82,532.00
|
| General & Administrative
Expenses |
$7.15 B
|
$8.43 M
|
$3.40 M
|
$442,145.00
|
$230,556.00
|
$301,464.00
|
| Selling & Marketing
Expenses |
-$7.15 B
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$6.64 M
|
$8.43 M
|
$3.40 M
|
$442,145.00
|
$230,556.00
|
$301,464.00
|
| Other Expenses |
$0.00 |
-$1.08 M |
-$278,333.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$19.42 M |
$17.59 M |
$5.87 M |
$726,604.00 |
$456,865.00 |
$384,518.00 |
| Cost And Expenses |
$19.42 M |
$17.59 M |
$5.87 M |
$726,604.00 |
$456,865.00 |
$384,518.00 |
| Interest Income |
$0.00 |
$20,410.00 |
$664.00 |
$136.00 |
$34.00 |
$68,922.00 |
| Interest Expense |
$50,614.00 |
$17.56 M |
$95,070.00 |
$394,573.00 |
$156,965.00 |
$0.00 |
| Depreciation &
Amortization |
$516,746.00
|
$98,606.00
|
$42,470.00
|
$726,604.00
|
$456,865.00
|
$383,996.00
|
| EBITDA |
-$17.97 M
|
-$17.47 M
|
-$6.11 M
|
$0.00
|
$0.00
|
-$69,444.00
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$872,421.00
|
$1.10 M
|
-$692,264.00
|
-$1.62 M
|
-$150,347.00
|
-$69,444.00
|
| Income Before Tax |
-$18.55 M |
-$17.56 M |
-$6.84 M |
-$2.34 M |
-$607,212.00 |
-$453,440.00 |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$17.56 M |
$95,070.00 |
$394,437.00 |
$156,931.00 |
-$69,444.00 |
| Net Income |
-$18.55 M |
-$35.13 M |
-$6.94 M |
-$2.74 M |
-$764,143.00 |
-$453,440.00 |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-103.61 |
-2195.62 |
-658.8 |
-343.19 |
-119.27 |
-70.77 |
| EPS Diluted |
-103.61 |
-2165.57 |
-658.8 |
-343.19 |
-119.27 |
-70.77 |
| Weighted Average Shares
Out |
$179,000.00
|
$16,000.00
|
$10,532.00
|
$7,979.00
|
$6,407.00
|
$6,407.00
|
| Weighted Average Shares
Out Diluted |
$179,006.00
|
$16,222.00
|
$10,532.00
|
$7,979.00
|
$6,407.00
|
$6,407.00
|
| Link |
|
|
|
|
|
|
